BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis-Reference-Cited by-同舟云学术

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Published:2004-10-01 Issue:19 Volume:64 Page:7099-7109
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Wilhelm Scott M.,Carter Christopher,Tang LiYa,Wilkie Dean,McNabola Angela,Rong Hong,Chen Charles,Zhang Xiaomei,Vincent Patrick,McHugh Mark,Cao Yichen,Shujath Jaleel,Gawlak Susan,Eveleigh Deepa,Rowley Bruce,Liu Li,Adnane Lila,Lynch Mark,Auclair Daniel,Taylor Ian,Gedrich Rich,Voznesensky Andrei,Riedl Bernd,Post Leonard E.,Bollag Gideon,Trail Pamela A.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 3590 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highly specific GSH-triggered bifunctional molecules to enable precise imaging and targeted therapy of cancer;Talanta;2025-01

2. Development and evaluation of biodegradable alginate beads loaded with sorafenib for cancer treatment;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2024-12

3. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

4. Inclusion complexes of regorafenib with beta- and gamma-cyclodextrin derivatives: In silico and in vitro studies;Journal of Molecular Liquids;2024-10

5. Sorafenib, a Tyrosine Kinase Inhibitor, Synergistically Enhances the Ferroptosis Effects of Asiatic Acid in Hepatocellular Carcinoma Cells;Environmental Toxicology;2024-09-12